Quantum Cyber N V (MYNZ) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Quantum Cyber N v   (MYNZ)


Quantum Cyber N V's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Quantum Cyber N V's ROI in the second quarter of 2026?
Quantum Cyber N V recorded a cumulative net loss of $-36 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -410.46%.

Within the Healthcare sector 214 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 0 to 4255.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 121.89 % 29.17 % -61.57 % -58.39 % -73.64 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 20 5 1 9 7
Return On Investment (TTM) -410.46 % -551.26 % -932.46 % -443.57 % -629.54 %
MYNZ's Overall Ranking # 4255 # 0 # 0 # #
Seq. Investment Change TTM 61.43 % 68.58 % -28.82 % 14.55 % -6.03 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -36 -30 -30 -20 -25

MYNZ Company Profile >> Back to MYNZ Roi Comparisons >> See Annual MYNZ Return On Investment



Return On Investment MYNZ's Ranking
Within: No.
Industry # 87
Sector # 215
Overall # 4255

Return On Investment Statistics
High Average Low
-164.94 %
-732.32 %
-1516.95 %
(Dec 31 2022)   (Dec 31 2025)



  News about Quantum Cyber N v Return on Investment ROI

A New Era in Diagnostics: Mainz Biomeds Strategic Leap Towards AI-Enhanced Biomarker Discovery and FDA Trials

October 1, 2024

In the ever-evolving landscape of healthcare, the integration of artificial intelligence (AI) has become a cornerstone of innovation, particularly in the challenging field of cancer diagnostics. Mainz Biomed N.V. (NASDAQ: MYNZ) stands at the forefront of this transformation, spearheading advancements aimed at early detection and management of pancreatic diseases through its innovative PancAlert platform. In a recent statement, the company’s CEO, Guido Baechler, outlined an ambitious plan for significant growth and U.S. FDA trials in 2025, signaling a crucial moment in the company’s trajectory and the broader medical diagnostic field.Strategic Partnership with Liquid Biosciences: Unlocking AI’s PotentialAs part of its strategy, Mainz Biomed has forged a strategic partnership with Liquid Biosciences, a collaboration set to amplify the efficacy of biomarker selection and optimization through the utilization of AI technologies. This partnership is particularly timely, as it aligns with the industry s increasing reliance on AI to streamline processes that historically required extensive time and resources for biomarker discovery. Specifically, the partnership aims to enhance the PancAlert platform, a sophisticated tool designed to improve diagnostic accuracy for pancreatic cancer and related disorders, conditions that have traditionally posed formidable challenges given their often-late diagnosis.

Harnessing AI for Enhanced Biomarker Selection Mainz Biomeds Strategic Partnership with Liquid Biosciences

September 4, 2024

Artificial Intelligence (AI) has emerged as a pivotal tool in pharmaceutical sciences, particularly in the realm of biomarker discovery. In this context, Mainz Biomed N.V. (NASDAQ: MYNZ) has announced a strategic partnership with Liquid Biosciences aimed at leveraging AI to enhance the selection and optimization of biomarkers for its PancAlert platform. This development signifies a potential leap forward in the early detection and management of pancreatic diseases, which have historically posed significant challenges in diagnostics.Mainz Biomed, a front-runner in the development of molecular diagnostics, is set on an ambitious trajectory to revolutionize the detection of pancreatic cancer and other related conditions through its PancAlert technology. The partnership with Liquid Biosciences comes at a critical juncture, as both firms seek to utilize AI s vast capabilities to streamline biomarker identification and validation processes.





Financial Statements
Quantum Cyber N V's II. Quarter Investments $ 20 Millions MYNZ's Balance sheet
Quantum Cyber N V's II. Quarter Income $ -11 Millions Quarterly MYNZ's Income Statement
MYNZ's Income by Division See MYNZ's Income by Division


MYNZ Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 2 7 6 16 9
Y / Y Investment Growth -75.8 % 13 % -61.25 % 86.42 % -
Net Income in Millions -16 -22 -26 -26 -12
Y / Y Net Income Growth - - - - -
Annual Return On Investment -944.46 % -305.29 % -418.99 % -162.91 % -134.54 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MYNZ's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MYNZ's Competitors
Subscribers only: Roi for Quantum Cyber N V's Suppliers
Subscribers only: Return On Investment for MYNZ's Customers

Other Ratios
MYNZ's Roa MYNZ's Inventory Turnover Ratio MYNZ's Growth Rates MYNZ's Dividend Statistics
MYNZ's Profitability Ratios MYNZ's Asset Turnover Ratio MYNZ's Dividend Growth
MYNZ's Roe MYNZ's Valuation Ratios MYNZ's Financial Strength Ratios MYNZ's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:41:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.